Using publicly available GEP datasets, we proved this hypothesis and showed that MTDH expression in MM cells from 142 newly-diagnosed patients was significantly decreased after Bortezomib treatment for 48h (PV) compared to the corresponding MM cells collected before treatment (BL) in the TT3 cohort (p=0.0121, (Figure 4C) [13, 18]. The gene discussed is MTDH; the disease is Miyoshi myopathy.